Ciprofloksacin
(IUPAC) ime | |||
---|---|---|---|
1-ciklopropil-6-fluoro-4-okso-7-(piperazin-1-il)-hinolin-3-karboksilna kiselina | |||
Klinički podaci | |||
Robne marke | Ciloxan, Cipro, Neofloxin | ||
AHFS/Drugs.com | Monografija | ||
MedlinePlus | a688016 | ||
Identifikatori | |||
CAS broj | 85721-33-1 | ||
ATC kod | J01MA02 S01AE03 S02AA15 S03AA07 | ||
PubChem[1][2] | 2764 | ||
DrugBank | DB00537 | ||
ChemSpider[3] | 2662 | ||
UNII | 5E8K9I0O4U Y | ||
KEGG[4] | D00186 Y | ||
ChEBI | CHEBI:100241 Y | ||
ChEMBL[5] | CHEMBL8 Y | ||
Hemijski podaci | |||
Formula | C17H18FN3O3 | ||
Mol. masa | 331,346 | ||
SMILES | eMolekuli & PubHem | ||
| |||
Farmakokinetički podaci | |||
Bioraspoloživost | 69%[6] | ||
Metabolizam | Hepatički, uključujući CYP1A2 | ||
Poluvreme eliminacije | 4 sata | ||
Izlučivanje | Renal | ||
Farmakoinformacioni podaci | |||
Licenca | US FDA:link | ||
Trudnoća | B3(AU) C(US) | ||
Pravni status | Samo na recept (S4) (AU) POM (UK) ℞-only (SAD) | ||
Način primene | Oralno, intravenozno, topikalno |
Ciprofloksacin (INN) pripada drugoj generaciji fluorohinolonskih antibiotika.[7][8] Njegov spektar delovanja obuhvata većinu sojeva bakterijskih patogena odgovornih za respiratorne, urinarne, gastrointestinalne, i abdomenalne infekcije, uključujući Gram-negativne (Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Legionella pneumophila, Moraxella catarrhalis, Proteus mirabilis, i Pseudomonas aeruginosa), i Gram-positivne (meticilin-senzitivni ali ne meticilin-rezistentni Staphylococcus aureus, Streptococcus pneumoniae, Staphylococcus epidermidis, Enterococcus faecalis, i Streptococcus pyogenes) bakterijske patogene. Ciprofloksacin i drugi fluorohinoloni su vredni zbog njihovog širokog spektra aktivnosti, odlične penetracije tkiva, kao i njihove dostupnosti u oralnim i intravenskim formulacijama.[9]
Reference
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
- ↑ Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J (September 1986). „Absolute oral bioavailability of ciprofloxacin”. Antimicrob Agents Chemother. 30 (3): 444–6. ISSN 0066-4804. PMC 180577. PMID 3777908.
- ↑ Nelson, JM.; Chiller, TM.; Powers, JH.; Angulo, FJ. (Apr 2007). „Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story.”. Clin Infect Dis 44 (7): 977–80. DOI:10.1086/512369. PMID 17342653.
- ↑ Kawahara, S. (Dec 1998). „[Chemotherapeutic agents under study]”. Nippon Rinsho 56 (12): 3096–9. PMID 9883617.
- ↑ Brunton, Laurence; Lazo, John; Parker, Keith (2005). Goodman & Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill Prof Med/Tech. ISBN 978-0-07-142280-2. Pristupljeno 30. 10. 2012.
Spoljašnje veze
Portal Medicina | |
Portal Hemija |
- Ciprofloksacin na Projektu Open Directory
- How Stuff Works - Cipro
- U.S. National Library of Medicine: Drug Information Portal - Ciprofloxacin
- Cipro Package Insert
- Proquin XR Package Insert
- Ciloxan Package Insert
- Ciprofloxacin Ophthalmic
- p
- r
- u
(inhibira
purinski metabolizam,
i tim putem inhibira
DNK i RNK sintezu)
Sulfonamidi (DS inhibitor) |
| ||||||
---|---|---|---|---|---|---|---|
Drugi/negrupisani | |||||||
Kombinacije |
topoizomeraze/
hinoloni/
(inhibiraju
DNK replikaciju)
|
inhibitori
Nitrofuran derivati |
---|
|